7 Mistakes MedTech Companies Make After FDA Clearance - And What to Do Instead

You spent two, maybe three years getting here. The 510(k) came through. The team celebrated. Now everyone’s asking the same question: when does revenue start?

The answer, more often than not, depends on what you do in the next 90 days. And most MedTech companies get it wrong; not because they lack smart people, but because they apply a consumer or pharma playbook to a market that doesn’t respond to either.

Here’s what we see, repeatedly, in companies that stall after clearance, and what separates the ones that don’t.

#1 Treating the FDA clearance as the product launch

Clearance is a regulatory event. Launch is a commercial one. These are not the same thing, and confusing them costs months.

We’ve seen companies spend six-figure sums on a clearance announcement — press release, investor update, LinkedIn fanfare — while the actual commercial infrastructure (surgeon messaging, rep training, reimbursement narrative, KOL activation plan) is still a deck in someone’s inbox.

By the time the commercial engine is ready to move, the news cycle has moved on, the momentum has dissipated, and your competitors have had a quarter to prepare a response.

The fix: Build your commercial launch plan in parallel with your regulatory process — not after. By clearance day, you should have your ICP defined, your first 10 target accounts identified, your KOL engagement underway, and your sales messaging locked. The announcement should be the starting gun, not the warm-up lap.

#2 Writing surgeon messaging for investors, not surgeons

This one is subtle but devastating. After years of fundraising, most MedTech leadership teams are fluent in investor language: TAM, clinical evidence, competitive differentiation, unmet need. That language makes a terrible first impression on a surgeon.

Surgeons are pattern-matching against their own experience. They want to know: *What problem does this solve for my specific patient population? How does it change my workflow? What’s my learning curve? What happened to the first 50 cases?*

When a device rep walks into an OR with messaging built for a pitch deck, the surgeon knows it in about 30 seconds. You don’t get a second first impression with a high-volume proceduralist.

The fix: Build your commercial messaging from the surgeon up. Talk to five surgeons who have no stake in your success. Ask them to describe the problem your device solves in their own words. Use their language. Build your value story around their workflow, not your clinical data table.

#3 Skipping KOL development because “we can’t afford it yet”

KOL engagement isn’t a luxury item you add after revenue. It *is* how you generate early revenue in MedTech — especially in specialties where surgeons trust peer influence over rep relationships.

The mistake isn’t investing in KOLs. It’s investing in the wrong ones, too late, without a clear activation strategy. We regularly see companies sign high-profile names to advisory boards and then have no structured plan for how those relationships translate into referrals, training, or market credibility.

The fix: Identify three to five surgeons who are respected within your target specialty and are genuinely excited about your technology. Invest deeply in those relationships — proctoring, case coverage, conference presentations, peer-to-peer programs. Build a documented engagement plan with measurable commercial milestones. Credibility in MedTech is local before it’s national.

#4 Waiting for reimbursement clarity before commercializing

Reimbursement is a process, not a prerequisite. Companies that wait for a clean coding and coverage story before commercializing often wait two to three years — years during which a competitor establishes the clinical standard, trains the surgeons, and owns the market.

This is especially common among PE and VC-backed companies that want to minimize commercial risk before reimbursement is resolved. The logic is understandable. The result is usually a market-entry problem they can’t recover from.

The fix: Commercialize into the reimbursement reality you have, not the one you’re hoping for. That means identifying the facility types and payer mixes where your device is already economically viable. Build a reimbursement story that’s honest about current coverage gaps while demonstrating a clear pathway. Train your clinical team to have the economics conversation alongside the clinical one.

#5 Building a sales team before building a sales system

Hiring a VP of Sales is not the same as having a commercial strategy. We’ve seen companies spend $800K on a national sales team in year one — territories, quotas, commission structures — before anyone has validated which customer segment closes fastest, what the true sales cycle looks like, or what objections kill deals.

The result is a year of expensive learning that should have taken 90 days with a leaner commercial experiment.

The fix: Instrument the early commercial process before you scale it. Use your first six months to identify your fastest-converting customer profile, your highest-leverage referral patterns, and your most common deal-killing objection. Build those findings into your hiring profile, training program, and territory model. Then scale.

#6 Letting brand drift during commercial build-out

When companies are heads-down on commercial execution, brand consistency tends to slip. The rep deck doesn’t match the website. The patient-facing materials don’t match the surgeon-facing materials. The social media presence has gone quiet. The company that had a sharp identity at launch looks fragmented six months in.

In MedTech, this matters more than most people think. Surgeons notice. Hospital value analysis committees notice. Investors evaluating your Series B notice.

The fix: Brand standards aren’t a marketing project — they’re a commercial infrastructure project. Establish a single source of truth for messaging, visual identity, and approved claims before you hire your first rep. Audit every customer-facing touchpoint quarterly. Consistency at this stage builds the kind of institutional credibility that accelerates both sales cycles and future fundraising.

#7 Measuring the wrong things in the first year

Vanity metrics feel reassuring and are nearly useless. Impressions. Website traffic. Social followers. Conference attendance. We’ve worked with companies that reported robust marketing activity for 12 months while their pipeline had three accounts in it.

The only metrics that matter in year one are the ones that connect directly to revenue: qualified leads per channel, time-to-first case, procedure adoption rate by account, referral velocity from early adopters. If you can’t draw a straight line from a marketing activity to one of those numbers, it probably shouldn’t be a priority.

The fix: Define your commercial success metrics before launch and build your reporting cadence around them. Every quarter, ask one question: which activities moved those numbers, and which didn’t? Kill what doesn’t move the needle, double down on what does.